Verdiva Bio
PVT · PVT·Guildford, United Kingdom·Private·Phase 2
Clinical-stage cardiometabolic company developing next-generation therapies for obesity. Lead program VRB-101 is a once-weekly oral GLP-1 peptide analog in Phase 2b for obesity. Launched in January 2025 with a $411M Series A co-led by Forbion and General Atlantic.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Verdiva Bio website | Website | May 6, 2026 | 4 |